Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a toll‐like receptor 2‐mediated cell‐penetrating peptide
Authors:
Open Access
- 20 November 2013
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 134 (3) , 692-702
Abstract
Cell‐penetrating peptides provide a unique platform to create a new generation of cancer therapeutics with enhanced efficacy and diminished toxicity. In our study, enhanced expression of toll‐like receptor 2 (TLR2) was observed in acute myeloid leukemia (AML) cells. Screening of a phage display peptide library using Biopanning and Rapid Analysis of Selective Interactive Ligands (BRASIL) identified a TLR2‐binding peptide motif, Pep2. We show that the TLR2‐binding peptide motif targeted and penetrated into leukemia cells in a TLR2‐dependent manner. Moreover, a synthetic, chimeric peptide composed of the TLR2‐binding motif linked to a programmed cell death‐inducing sequence, D(KLAKLAK)2, induced apoptosis in AML cells with high TLR2 expression (TLR2high) but not in chronic myeloid leukemia (CML) cells with low TLR2 expression (TLR2low). The antileukemia activity of this chimeric peptide was confirmed in leukemia patient samples and an animal model of myeloid leukemia, as the development of leukemia was significantly delayed in mice with TLR2high AML compared to TLR2low CML NOD/SCID mice. TUNEL assays on bone marrow tissue slices revealed that the chimerical peptide induced leukemia cell apoptosis in a TLR2‐dependent manner. Together, our findings indicate that TLR2 is a potential therapeutic target for the prevention and treatment of AML, and the prototype, Pep2‐D(KLAKLAK)2, is a promising drug candidate in this setting.Keywords
This publication has 45 references indexed in Scilit:
- Promiscuous Binding of Invariant Chain-Derived CLIP Peptide to Distinct HLA-I Molecules Revealed in Leukemic CellsPLOS ONE, 2012
- Molecular Action of Lenalidomide in Lymphocytes and Hematologic MalignanciesAdvances in Hematology, 2012
- Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy IndividualizationPLOS ONE, 2011
- Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancerCancer Immunology, Immunotherapy, 2011
- Mycobacterium tuberculosis Lipoproteins Directly Regulate Human Memory CD4 + T Cell Activation via Toll-Like Receptors 1 and 2Infection and Immunity, 2011
- Targeting neuropilin-1 in human leukemia and lymphomaBlood, 2011
- Induction of Cancer Cell Death by Self-assembling Nanostructures Incorporating a Cytotoxic PeptideCancer Research, 2010
- Blocking TLR2 Activity Attenuates Pulmonary Metastases of TumorPLOS ONE, 2009
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialBlood, 2008
- An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsBlood, 2007